TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02480244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control arm receives no health-related behavioral intervention
Study: NCT02763150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Intervention group will receive comprehensive behavioral weight loss program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion
Description: The health promotion group will receive education on healthy eating and activity
Study: NCT01009762

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peptide vaccine (AFO-18)
Description: 18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
Study: NCT02229396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exantide with Dapagliflozin
Description: 2 mg weekly suspension injection and 10 mg Dapagliflozin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exentide
Description: 2 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10 mg once daily Dapagliflozin
Study: NCT01987232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered by intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Administered by intravenous infusion.
Study: NCT01072513

Intervention type: OTHER
Group type: OTHER
Intervention: Semen analysis
Description: Semen analysis before and after proton radiation therapy.
Study: NCT03409900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPB
Description: The LPB will be performed in a lateral position, but modified to utilize ultrasound guidance to enhance our ability to quickly and safely locate the lumbar plexus as well as to avoid unblinding with regard to the traditional landmark LPB technique. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QLB
Description: The QLB will be performed in a lateral position in a manner consistent with the technique first described by Børglum. For both LPB and QLB a TOTAL DOSE of 20 cc of the following local anesthetic mixture will be administered: Ropivacaine 0.2% and Epinephrine - 2.5 mcg/cc (1:400,000 concentration).
Study: NCT00985517

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CERE-120: Adeno-Associated Virus Delivery of Neurturin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CERE-120: Adeno-Associated Virus Delivery of Neurturin

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CERE-120: Adeno-Associated Virus Delivery of Neurturin

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Surgery
Study: NCT01471509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water, glucose with or without amino acid
Description: 240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water, glucose with or without amino acid
Description: 240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water, glucose with or without amino acid
Description: 240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water, glucose with or without amino acid
Description: 240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
Study: NCT00503451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBH589
Study: NCT03909113

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: amino acid based formula
Description: amino acid based formula
Study: NCT03785899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPOCnew
Description: SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPOCnew
Description: SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The revised new algorithm is turned on.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 8s.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 8s.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPOCold
Description: SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPOCold
Description: SPOC is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (SPO2). The former old algorithm is turned on.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 2s.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2s SpO2 averaging
Description: The arterial saturation (SPO2) will be averaged over 2s.
Study: NCT03147300

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current routine practice
Description: Current routine practice for the primary care management of LBP
Study: NCT02645773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-ablative laser
Description: non-abaltive laser pre, immediate and post wounding

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-ablative laser
Description: non-abaltive laser pre, immediate and post wounding

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-ablative laser
Description: non-abaltive laser pre, immediate and post wounding
Study: NCT00397137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Circular stapled anopexy
Description: Patients receiving stapled anopexy to treat haemorrhoids

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed diathermy haemorrhoidectomy
Description: Conventional haemorrhoidectomy as described by Ferguson method
Study: NCT03666208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus Coated Balloon
Description: Sirolimus has been used in organ transplantation as well as coronary stent due to its antiproliferative properties. It has been proven to has better outcome in animal studies compared to paclitaxel, which is about 22% in the sirolimus group versus 75% re-stenosis rate in paclitaxel group.~Sirolimus is coated on the surface of the angioplasty balloon and is transferred to the vessel wall when balloon is inflated and in contact with the vessel wall.~The following table compare sirolimus to paclitaxel. In which sirolimus works by cytostatic mechanism with a ten thousand fold of safety margin. And sirolimus's anti-restenosis effect is optimal with the benefit of lower level of competition and lesser tissue absorption and elution.
Study: NCT02452125

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine chewing gum
Study: NCT02927899

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato-Soy Juice
Description: Receive tomato-soy beverages with or without varying levels of arugula seed powder
Study: NCT02456298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard FA+FCT
Description: Standard Functional Analysis and Functional Communication Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pragmatic FA+FCT
Description: Pragmatic Functional Analysis and Functional Communication Training
Study: NCT00726388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DIC075V (intravenous diclofenac sodium)
Description: multiple doses up to 5 days
Study: NCT02941432

Intervention type: OTHER
Group type: OTHER
Intervention: Black tea compress treatment
Description: Wet compresses with black tea applied 4-5 times daily to the face for 6 days
Study: NCT01011049

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine USP Trivalent Types A and B
Description: 0.1 mL, Intradermal
Study: NCT02312622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Irinotecan
Description: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Irinotecan
Description: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Irinotecan
Description: Administered intravenously (IV) at 145 mg/m² as monotherapy once every 21 days (1 cycle)
Study: NCT01297699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (RoActemra®)
Description: Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile 0.9% Sodium Chloride
Description: Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
Study: NCT04010383

Intervention type: DIAGNOSTIC_TEST
Intervention: virtual reality perimeter
Description: Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.

Intervention type: DIAGNOSTIC_TEST
Intervention: virtual reality perimeter
Description: Both groups will be examined with a standard automated perimeter as well as with the virtual reality perimeter.
Study: NCT04441996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE)
Description: Participants will receive two treatments of TPE with frozen plasma (FP) replacement on two sequential days (Day 2 and Day 3). All procedures will be performed by the apheresis staff at the hospital sites, following institutional standard operating procedures. FP will be obtained from American Red Cross or LifeSouth Community Blood centers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Participants will continue to receive standard of care and be closely monitored by ICU team for any change in clinical status, and any adverse events directly related to study intervention will be reported to the study investigator.
Study: NCT01053897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GBT009
Description: Intradermal Injection following surgery

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal Injection following surgery
Study: NCT02001389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6308
Description: Arms 1, 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6308
Description: Arms 1, 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6308
Description: Arms 1, 2, 3, 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVP-6308
Description: Arms 1, 2, 3, 4
Study: NCT02125097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barrel™ Vascular Reconstruction Device (VRD)
Description: Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio \< 2.
Study: NCT03849521

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Enhanced carotid calcification presented by UTE MR.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Enhanced carotid calcification presented by UTE MR.
Study: NCT01191697

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given intravenously on day 1 of each cycle beginning cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given intravenously on day 1 of each treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given intravenously on day one of each cycle beginning cycle 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Taken orally on days 1-14 of each cycle beginning cycle 2
Study: NCT03147300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multifaceted implementation of the BetterBack
Description: The multifaceted intervention is composed of the following:~1. Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.~2. Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.~3. Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.~4. Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians.
Study: NCT04489849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 MG
Description: apixaban 2.5mg BID for 3 months in experimental group

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Medication other than anticoagulation
Study: NCT04398186

Intervention type: DIAGNOSTIC_TEST
Intervention: Anogenital distance measurement
Description: Measurements of AGD and perineal muscle strength

Intervention type: DIAGNOSTIC_TEST
Intervention: Anogenital distance measurement
Description: Measurements of AGD and perineal muscle strength

Intervention type: DIAGNOSTIC_TEST
Intervention: Anogenital distance measurement
Description: Measurements of AGD and perineal muscle strength

Intervention type: DIAGNOSTIC_TEST
Intervention: Anogenital distance measurement
Description: Measurements of AGD and perineal muscle strength
Study: NCT03567512

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking hygiene intervention
Description: The Smoking Hygiene Intervention(SHI) will be delivered in six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes). The intervention, SHI, will address SHS exposure of children and parental quitting. It will include behavioral counseling to address health hazards of SHS for children, advice to quit smoking and to adopt a no smoking policy around children and self-help materials (related to second-hand smoking and quitting smoking).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo intervention
Description: The placebo intervention will include developmental perspective of the child at different stages of their life, advice on educational and emotional perspective of the child, discussion on the nutritional issues of the child, and self-help materials describing the child development issues.~Subjects randomized to control group will receive a placebo intervention on child development issues delivered at six different individualized counseling sessions (two in-person and four telephone counseling): the initial in-person counseling (30-45 minutes), 1 week telephone counseling (\~20 minutes), 2 week telephone counseling (\~20 minutes), 1 month in-person counseling (15-30 minutes), 2 month telephone counseling (\~20 minutes), and 4 month telephone counseling (\~20 minutes).
Study: NCT03838237

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiological evaluation
Description: Baseline evaluation~* FAbry STabilization indEX (FASTEX)~* 12 leads ECG~* Blood samples for microRNA, TnT HS and NT-proBNP dosages~* 2D echocardiogram~* Cardio-pulmonary test~* Contrast-enhanced CMR including:~  * Cine images~ * T2 mapping sequences~ * T1 mapping sequences before and 15' after contrast medium administration~ * Late Gadolinium Enhancement (LGE) imaging~ * Phase contrast images (LVOT, aortic flow)~Follow up evaluation~•After 18 months, the same procedures will be repeated
Study: NCT02686658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 20 mg/mL solution for intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 20 mg/mL solution for intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 20 mg/mL solution for intravitreal (IVT) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 20 mg/mL solution for intravitreal (IVT) injection

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham
Description: The Sham procedure included the blunt opening of an empty, needleless syringe barrel placed on the conjunctiva in the inferotemporal quadrant of the eyeball to simulate the pressure of an injection.
Study: NCT01046032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
Study: NCT00825656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinol or Sinol-M nasal spray
Description: One spray in each nostril up to a maximum of 12 times / day on an as needed basis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinol or Sinol-M nasal spray
Description: One spray in each nostril up to a maximum of 12 times / day on an as needed basis
Study: NCT02096068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dexdor®)
Description: Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
Study: NCT00821223

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification and SICS
Description: SICS with rigid IOL implantation Phaco with foldable IOL implantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: manual small incision surgery

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phacoemulsification
Description: cataract surgery
Study: NCT01236781

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Screening Tomosynthesis
Description: Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic Tomosynthesis
Description: Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
Study: NCT02978391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UI-EWD Hemostatic system
Description: Adhesive endoscopic hemostats, powder type

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epinephrine endoscopic injection (conventional therapy)
Description: endoscopic submucosal injection of epinephrine (1: 10,000)
Study: NCT03679286

Intervention type: DEVICE
Intervention: PCM and ROTEM
Description: Test of blood sample by both PCM and ROTEM
Study: NCT02718248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CHESS Mobile Health smart phone application
Description: A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Description: Face to face problem solving therapy every week for six weeks.
Study: NCT01238718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: lidocaine 1.5 mg/kg intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline